Noninvasive focal gene transfer of chemogenetic proteins in the primate brain.
Authors: Corigliano MR, Parks TV, Guretse SS, Letica L, Zimmermann Rollin I, Pell SKA, Campos VP, Szczupak D, Schaeffer DJ
The development of chemogenetic neuromodulators, including Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), have enabled focally specific, long-lasting, and reversible neuromodulation in the primate brain. Although systemically delivered synthetic ligands allow for noninvasive actuation of chemogenetic receptors, direct intraparenchymal injection remains atop the available methods to precisely deliver chemogenetic payloads to a specific target of the brain. The requirement of trephination, however, is accompanied by inherent risks of infection, long recovery times, and often tissue damage with concomitant behavioral complications. When considering therapeutic injections, the requirement of transcranial surgery does not translate well to the clinic, especially when repeated administrations are required. Here, we leverage our recent development of transcranial focused ultrasound (tFUS) for noninvasive and focal delivery of adeno-associated viruses (AAVs) carrying excitatory Gq-DREADDs to frontal cortical targets (areas 6DR and 8aD) in the marmoset brain. Using [ <sup>18</sup> F]-fluorodeoxyglucose (FDG) positron emission tomography, we demonstrate significant increases in glucose metabolism at the site of viral delivery after administering the DREADD-specific agonist deschloroclozapine (DCZ), as compared to vehicle control. Focal neuronal DREADD expression was confirmed by immunohistochemistry at the site of opening. Through comparison of awake resting-state functional connectivity (whole brain connectivity with the sites of delivery) and structural connectivity (directly injected viral neuronal tracing at the sites of delivery) we demonstrate that the increase in glucose metabolism occurs at both mono- and polysynaptically connected brain regions. Taken together, these results demonstrate the ability to focally deliver excitatory chemogenetics without the need for surgery, allowing for activation of long-range frontal cortex circuits of the primate brain.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To demonstrate that transcranial focused ultrasound can noninvasively and focally deliver excitatory Gq-DREADD AAVs to primate frontal cortex and activate long-range circuits.
Animal model / Human subject
Common marmoset (Callithrix jacchus); strain: None; age: None; sex: None
Targeted brain region(s)
Frontal Cortex (Areas 6Dr And 8Ad)
Cargo name and characteristics
Adeno-associated virus (AAV) vector carrying an excitatory Gq-DREADD (chemogenetic receptor) for focal neuronal expression in frontal cortex (areas 6DR and 8aD) in marmosets; DREADD activation was achieved using the small-molecule agonist deschloroclozapine (DCZ).
Route of administration
Transcranial focused ultrasound (tFUS) for noninvasive, focal delivery of AAVs carrying Gq-DREADDs
Outcomes and Safety
Summary of Outcomes
Transcranial focused ultrasound-mediated AAV delivery of excitatory Gq-DREADDs to frontal cortex in marmosets produced focal DREADD expression and, after systemic deschloroclozapine, significant increases in glucose metabolism at the delivery sites and in mono- and polysynaptically connected regions, demonstrating noninvasive activation of long-range frontal circuits (focused ultrasound parameters None).
Safety-related matter
The paper notes that trephination (transcranial surgery) carries inherent risks of infection, long recovery times, tissue damage, and concomitant behavioral complications, making repeated clinical administrations problematic; no adverse effects of the noninvasive tFUS-AAV delivery method are reported in the abstract.
Brain Region
Ultrasound Parameters
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: None
Treatment frequency
Single
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search